38 research outputs found

    Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Get PDF

    Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma

    No full text
    5T4 (trophoblast glycoprotein, TPBG) is a transmembrane tumor antigen expressed on more than 90% of primary renal cell carcinomas (RCC) and a wide range of human carcinomas but not on most somatic adult tissues. The favorable expression pattern has encouraged the development and clinical testing of 5T4-targeted antibody and vaccine therapies. 5T4 also represents a compelling and unexplored target for T-cell receptor (TCR)-engineered T-cell therapy. Our group has previously isolated high-avidity CD8 + T-cell clones specific for an HLA-A2-restricted 5T4 epitope (residues 17–25; 5T4 p17 ). In this report, targeted single-cell RNA sequencing was performed on 5T4 p17 -specific T-cell clones to sequence the highly variable complementarity-determining region 3 ( CDR3 ) of T-cell receptor α chain ( TRA ) and β chain ( TRB ) genes. Full-length TRA and TRB sequences were cloned into lentiviral vectors and transduced into CD8 + T-cells from healthy donors. Redirected effector T-cell function against 5T4 p17 was measured by cytotoxicity and cytokine release assays. Seven unique TRA - TRB pairs were identified. All seven TCRs exhibited high expression on CD8 + T-cells with transduction efficiencies from 59 to 89%. TCR-transduced CD8 + T-cells demonstrated redirected cytotoxicity and cytokine release in response to 5T4 p17 on target-cells and killed 5T4 + /HLA-A2 + kidney-, breast-, and colorectal-tumor cell lines as well as primary RCC tumor cells in vitro. TCR-transduced CD8 + T-cells also detected presentation of 5T4 p17 in TAP1/2 -deficient T2 target-cells. TCR-transduced T-cells redirected to recognize the 5T4 p17 epitope from a broadly shared tumor antigen are of interest for future testing as a cellular immunotherapy strategy for HLA-A2 + subjects with 5T4 + tumors
    corecore